Effects of palmitoylethanolamide on aqueous humor outflow

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 8, 2012, Pages 4416-4425

  Kumar, Akhilesh ^a   Qiao, Zhuanhong ^a   Kumar, Pritesh ^a   Song, Zhao Hui ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1, 3, 3 TRIMETHYLBICYCLO [2.2.1] HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 2 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; G PROTEIN COUPLED RECEPTOR; GW 6471; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; RIMONABANT; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTERIOR EYE SEGMENT; AQUEOUS HUMOR OUTFLOW; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAOCULAR HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SWINE; TRABECULAR MESHWORK; VIRUS CULTURE; WESTERN BLOTTING;

ANIMALS; AQUEOUS HUMOR; BLOTTING, WESTERN; BORNANES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; ORGAN CULTURE TECHNIQUES; OXAZOLES; PALMITIC ACIDS; PHOSPHORYLATION; PIPERIDINES; PPAR ALPHA; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; SWINE; TRABECULAR MESHWORK; TYROSINE;

EID: 84863757562     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-9294     Document Type: Article

References (46)

1. Crowston JG, Weinreb RN. Glaucoma medication and aqueous humor dynamics. Curr Opin Ophthalmol. 2005;16:94-100.
2. Quigley HA, Broman AT, The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
3. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711-1720.
4. Green K. Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthalmol. 1998;116:1433-1437.
5. Hepler RS, Frank IR. Marihuana smoking and intraocular pressure (Letter to the Editor). JAMA. 1971;217:1392.
6. Stamer WD, Golightly SF, Hosohata Y, et al. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol. 2001;431:277-286.
7. Njie YF, Kumar A, Qiao Z, Zhong L, Song ZH. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest Ophthalmol Vis Sci. 2006;47:1999-2005.
8. Zhong L, Geng L, Njie Y, Feng W, Song ZH. CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest Ophthalmol Vis Sci. 2005;46:1988-1992.
9. Njie YF, He F, Qiao Z, Song ZH. Aqueous humor outflow effects of 2-arachidonylglycerol. Exp Eye Res. 2008;87:106-114.
10. Njie YF, Qiao Z, Xiao Z, Wang W, Song ZH. N-Arachidonylethanolamide-induced increase in aqueous humor outflow facility. Invest Ophthalmol Vis Sci. 2008;49:4528-4534.
11. Bachur NR, Masek K, Melmon KL, Udenfriend S. Fatty acid amides of ethanolamine in mammalian tissues. J Biol Chem. 1965;240:1019-1024.
12. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
13. Bachur NR, Udenfriend S. Microsomal synthesis of fatty acid amides. J Biol Chem. 1966;241:1308-1313.
14. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem. 1997;272: 3315-3323.
15. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life Sci. 2005; 77:1685-1698.
16. Chen J, Matias I, Dinh T, et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun. 2005;330:1062-1067.
17. Pescosolido N, Librando A, Puzzono M, Nebbioso M. Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study. J Ocul Pharmacol Ther. 2011;27:629-635.
18. Gagliano C, Ortisi E, Pulvirenti L, et al. Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial. Invest Ophthalmol Vis Sci. 2011;52:6096-6100.
19. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002;135: 181-187.
20. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 1998;76:189-199.
21. Godlewski G, Offertaler L, Wagner JA, Kunos G. Receptors for acylethanolamides-GPR55 and GPR119. Prostag Other Lipid Mediat. 2009;89:105-111.
22. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007; 152:1092-1101.
23. Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67:15-19.
24. Duncan RS, Chapman KD, Koulen P. The neuroprotective properties of palmitoylethanolamine against oxidative stress in a neuronal cell line. Mol Neurodegener. 2009;4:50.
25. Lepicier P, Bouchard JF, Lagneux C, Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol. 2003;139:805-815.
26. Shearer T, Crosson CE. Activation of extracellular signalregulated kinase in trabecular meshwork cells. Exp Eye Res. 2001;73:25-35.
27. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogenactivated protein kinase kinase in vitro and in vivo. J Biol Chem. 1995;270:27489-27494.
28. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
29. Polansky JR, Weinreb RN, Baxter JD, Alvarado J. Human trabecular cells. I. Establishment in tissue culture and growth characteristics. Invest Ophthalmol Vis Sci. 1979;18:1043-1049.
30. Tripathi RC, Tripathi BJ. Human trabecular endothelium, corneal endothelium, keratocytes, and scleral fibroblasts in primary cell culture. A comparative study of growth characteristics, morphology, and phagocytic activity by light and scanning electron microscopy. Exp Eye Res. 1982;35:611-624.
31. Piomelli D, Tarzia G, Duranti A, et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006;12:21-38.
32. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240-244.
33. Rinaldi-Carmona M, Barth F, Millan J, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 1998;284:644-650.
34. Xu HE, Stanley TB, Montana VG, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature. 2002;415:813-817.
35. Bantounas I, Phylactou LA, Uney JB. RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol. 2004;33:545-557.
36. Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol. 2004;88:708-713.
37. He F, Song ZH. Molecular and cellular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cells. Mol Vis. 2007;13:1348-1356.
38. Kumar A, Song ZH. CB1 cannabinoid receptor-mediated changes of trabecular meshwork cellular properties. Mol Vis. 2006;12:290-297.
39. Mikawa Y, Matsuda S, Kanagawa T, Tajika T, Ueda N, Mimura Y. Ocular activity of topically administered anandamide in the rabbit. Jpn J Ophthalmol. 1997;41:217-220.
40. Straiker AJ, Maguire G, Mackie K, Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci. 1999;40:2442-2448.
41. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferatoractivated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49:497-505.
42. Gardner OS, Dewar BJ, Graves LM. Activation of mitogenactivated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol Pharmacol. 2005;68:933-941.
43. LoVerme J, Russo R, La Rana G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther. 2006;319:1051-1061.
44. Rojas CV, Greiner RS, Fuenzalida LC, Martinez JI, Salem N Jr, Uauy R. Long-term n-3 FA deficiency modifies peroxisome proliferator-activated receptor beta mRNA abundance in rat ocular tissues. Lipids. 2002;37:367-374.
45. Shearer TW, Crosson CE. Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2002;43:3016-3020.
46. Alexander JP, Acott TS. Involvement of the Erk-MAP kinase pathway in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs. Invest Ophthalmol Vis Sci. 2003;44: 164-169.